# Anti-IgLON5 encephalitis is associated with anti-retinal immunological reactivity without retinal alteration

**Authors:** Marie Rafiq, Fanny Varenne, Jérémie Pariente, Fabienne Ory-Magne, Marie Wolfrum, Fleur Gérard, Laurine Virchien, Anne-Laurie Pinto, Bastien Joubert, Françoise Fortenfant, Damien Biotti, Chloé Bost

PMC · DOI: 10.1016/j.jtauto.2026.100359 · Journal of Translational Autoimmunity · 2026-02-16

## TL;DR

This study explores retinal involvement in anti-IgLON5 encephalitis, finding anti-retinal antibodies despite no visible retinal damage.

## Contribution

The study reveals anti-retinal immunological reactivity in anti-IgLON5 encephalitis patients without retinal alterations.

## Key findings

- All patients showed specific anti-retinal antibody staining in the inner plexiform layer.
- Ophthalmological exams revealed no common morphological or electrophysiological abnormalities.
- The findings suggest a possible role for the retina in the disease's pathophysiology.

## Abstract

Anti-IgLON5 disease is a recently defined autoimmune disorder of the central nervous system associated with autoantibodies against IgLON5. This progressive condition, combining features of autoimmunity and neurodegeneration, presents with highly heterogeneous symptoms, including sleep disorders, bulbar symptoms, oculomotor dysfunction, gait disturbances, and subsequent cognitive decline. Recent reports have also described cases of papillitis. The target antigen, IgLON5, is a cell adhesion protein whose role is not fully understood. In humans, it is mainly expressed in the brain and testis. IgLON5 transcripts are also expressed in the retina. However, retinal involvement is not classically explored in these patients. In this cross-sectional observational study, we investigated whether anti-IgLON5 antibodies might target retinal structures, and correlated these findings with ophthalmological assessments. Six patients were diagnosed with anti-IgLON5 antibody encephalitis at Toulouse University Hospital. Identification of the anti-IgLON5 antibody was performed by immunofluorescence on transfected cells using serum and CSF. Anti-retinal antibodies were detected by an indirect immunofluorescence method on sections of monkey retina. Patients underwent a systematic ophthalmological examination including an anatomical and electrophysiological assessment. Anti-retinal antibody identification revealed specific staining of the inner plexiform layer in all patients, which was not observed in control individuals. However, morphological and electrophysiological ophthalmological examinations did not reveal any common features between the patients. Although retinal involvement is rarely reported, these findings suggest a possible role for the retina in the pathophysiology of anti-IgLON5 encephalitis. They support the relevance of considering ophthalmological monitoring in patients with IgLON5-related disease.

## Linked entities

- **Genes:** IGLON5 (IgLON family member 5) [NCBI Gene 402665]
- **Proteins:** IGLON5 (IgLON family member 5)
- **Diseases:** papillitis (MONDO:0006879)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** LOC102723407 (immunoglobulin heavy variable 4-38-2-like) [NCBI Gene 102723407] {aka IGHV4, IGHV4-30, IGHV4-38-2, IGHV4-39, IGHV4-b, IGVH4-39}, CSF2 (colony stimulating factor 2) [NCBI Gene 1437] {aka CSF, GMCSF}, RCVRN (recoverin) [NCBI Gene 5957] {aka RCV1}, Iglon5 (IgLON family member 5) [NCBI Gene 210094] {aka A230106M20Rik, Gm1431}, HLA-DRB1 (major histocompatibility complex, class II, DR beta 1) [NCBI Gene 3123] {aka DRB1, HLA-DR1B, HLA-DRB, SS1}, IGLON5 (IgLON family member 5) [NCBI Gene 402665]
- **Diseases:** neuropapillitis (MESH:D009902), anti-Hu encephalitis (MESH:D004660), macular edema (MESH:D008269), Diabetic Retinopathy (MESH:D003930), retinal involvement (MESH:D012173), pleocytosis (MESH:D007964), ptosis (MESH:C564553), gaze disorder (MESH:D015835), retina impairment (MESH:D019572), daytime hypersomnolence (MESH:D006970), death (MESH:D003643), epiretinal membrane (MESH:D019773), vertical/horizontal gaze paralysis (MESH:C564593), sleep apnea (MESH:D012891), cognitive decline (MESH:D003072), neuronal damage (MESH:D009410), obstructive sleep apnea (MESH:D020181), cataract (MESH:D002386), right tilted disc syndrome (MESH:D055959), gait ataxia (MESH:D020234), abnormal movements (MESH:D004409), ophthalmological (MESH:C536647), ocular or retinal damage (MESH:D012164), CAR syndrome (MESH:D056733), trismus (MESH:D014313), neuroinflammation (MESH:D000090862), melanoma-associated retinopathy (MESH:D059545), bulbar syndrome (MESH:D014854), inflammatory (MESH:D007249), optic disc edema (MESH:D010211), neurodegeneration (MESH:D019636), Anti-IgLON5 disease (MESH:D004194), parasomnias (MESH:D020447), loss of (MESH:D016388), OCT (MESH:D009901), visual acuity loss (MESH:D014786), sleep disorders (MESH:D012893), optic atrophy (MESH:D009896), antibody-mediated diseases (MESH:D020274), balance disturbances (MESH:D014832), chorea (MESH:D002819), macular detachment (MESH:D012163), paraneoplastic neurological syndrome (MESH:D020361), neurological disorders (MESH:D009461), IgG4 (MESH:D000077733), cerebellar atrophy (MESH:D002526), gait disturbances (MESH:D020233), respiratory failure (MESH:D012131), corneal opacities (MESH:D003318), autoimmune disease (MESH:D001327), horizontal-rotatory nystagmus (MESH:D009759), Oculomotor abnormalities (MESH:D015840), chronic central serous chorioretinopathy (MESH:D056833), autoimmune retinopathies (MESH:D058437)
- **Chemicals:** fluorescein (MESH:D019793), Rituximab (MESH:D000069283), CYC (-), FITC (MESH:D016650), Cyclophosphamide (MESH:D003520), RTX (MESH:C024353)
- **Species:** Homo sapiens (human, species) [taxon 9606], Cercopithecidae (monkey, family) [taxon 9527], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** HEK293 — Homo sapiens (Human), Transformed cell line (CVCL_0045)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12934314/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12934314/full.md

## References

23 references — full list in the complete paper: https://tomesphere.com/paper/PMC12934314/full.md

---
Source: https://tomesphere.com/paper/PMC12934314